Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals (PVCT) specializes in developing innovative immunotherapies for solid tumor cancers, with its lead investigational drug PV-10 demonstrating potential through tumor ablation and immune system activation. This page serves as the definitive source for verified company updates across all clinical and corporate developments.
Investors and researchers will find chronologically organized press releases detailing clinical trial progress, regulatory communications, and strategic partnerships. Our curation focuses on material events including phase trial results, FDA interactions, and intellectual property updates directly impacting PVCT's valuation trajectory.
Content spans three key areas: clinical research milestones across melanoma, breast, and liver cancer studies; corporate strategy announcements including licensing agreements and financing activities; and scientific publications validating PV-10's dual ablation-immunotherapy mechanism. All materials are sourced from official company disclosures to ensure accuracy.
Bookmark this page for streamlined tracking of PVCT's progress in advancing localized cancer therapies. For comprehensive analysis of how these developments may influence long-term growth potential, consult your financial advisor alongside these primary sources.
Provectus Biopharmaceuticals (OTCQB: PVCT) announced the publication of preclinical research on PV-10 for head and neck squamous cell carcinoma (HNSCC) in Molecular Cancer Therapeutics. The research, conducted by Dr. Christine Chung's team at Moffitt Cancer Center, revealed novel mechanistic findings about PV-10's ability to trigger immunogenic cell death in HNSCC through endoplasmic reticulum stress and apoptosis.
The company plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt Cancer Center later in 2025. PV-10 is Provectus's investigational cancer immunotherapy formulated from pharmaceutical-grade rose bengal sodium (RBS).
Provectus Biopharmaceuticals (OTCQB: PVCT) announced a $3 million seed financing round for its spinoff company, VisiRose. VisiRose is a clinical-stage biotechnology company focused on developing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) for treating infectious keratitis and other eye infections. RB-PDAT uses Provectus's bioactive synthetic small molecule, Rose Bengal Sodium (RBS), combined with a light-based medical device from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute.
The financing will support several key initiatives: preparing for a pre-IND submission meeting with the FDA for RB-PDAT, submitting an IND application for the investigational eye drug PV-305, manufacturing an initial clinical supply of PV-305, and applying for Small Business Innovative Research grant funding. Dominic Rodrigues, Vice Chairman of Provectus and Acting CEO of VisiRose, expressed optimism about advancing VisiRose's ophthalmology drug pipeline.
VisiRose's website is accessible at: visirose.com
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched VisiRose, Inc., its first Founded Entity, focusing on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for treating infectious keratitis and serious eye infections. The University of Miami is a minority shareholder in VisiRose.
The treatment combines Provectus's pharmaceutical-grade Rose Bengal Sodium (RBS) API with a light-based medical device developed at the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute. RB PDAT is designed to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Provectus Biopharmaceuticals (OTCQB: PVCT) has scheduled its Fourth Quarter 2024 Investor Update webinar via Zoom for Thursday, November 14, 2024, at 2 p.m. EST. Interested participants can access the conference call by registering in advance through the provided Zoom registration link.
Provectus Biopharmaceuticals (OTCQB: PVCT) has announced a conference call scheduled for Thursday, November 14, 2024 at 2 p.m. EST. The purpose of the call is to provide Company updates. Provectus has stated that the conference call details will be shared closer to the event date. This announcement indicates that the company is planning to communicate important information to its stakeholders, which could potentially include updates on financial performance, research and development progress, or other significant business developments.
Provectus Biopharmaceuticals announced an investor webinar for its 2024 annual stockholder meeting. The meeting will take place on June 20, 2024, at the Hilton Knoxville and will also be accessible via Zoom Webinar. Only stockholders of record as of April 24, 2024, may vote at the meeting by attending in person or through proxy materials. While the webinar provides an update and meeting activities overview, it does not count for quorum or voting purposes. Proxy materials and the 2023 Annual Report are available on the company's website and the SEC's website.
Provectus Biopharmaceuticals announced non-clinical data on its rose bengal sodium (RBS) for treating full-thickness cutaneous wounds at the Society for Investigative Dermatology (SID) 2024 Annual Meeting. The study, led by Dr. Amina El Ayadi at the University of Texas Medical Branch, revealed that RBS treatment accelerated wound closure, reduced transepidermal water loss, increased collagen density, and improved vascularity with no toxicity or adverse effects. These findings suggest that RBS could enhance wound healing and prevent fibrosis, making it a promising treatment for severe skin wounds.
Provectus Biopharmaceuticals (OTCQB: PVCT) announced clinical and non-clinical data presentations on rose bengal photodynamic antimicrobial therapy (RB PDAT) at the ARVO 2024 Annual Meeting held May 5-9 in Seattle. The company has entered an exclusive worldwide license agreement with the University of Miami to commercialize RB PDAT for treating various eye infections. They plan to form a start-up, Eyecare NewCo, by Q3 2024. Presentations covered diverse aspects of RB PDAT, including safety and effectiveness. RB PDAT is currently in two Phase 3 trials and has been used in the U.S., India, Brazil, and Mexico.
Provectus Biopharmaceuticals, Inc. announced the allowance of a U.S. patent for the oral administration of Rose Bengal Sodium in treating hematologic cancers, including leukemia. The patent covers the use of Provectus's pharmaceutical grade RBS for therapy in pediatric and adult leukemias. This marks a significant development in the company's patent portfolio, showcasing their commitment to innovation and potential in cancer treatment.
FAQ
What is the current stock price of Provectus Biopha (PVCT)?
What is the market cap of Provectus Biopha (PVCT)?
